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Abstract - Headache occipital neuralgia is an example of 
pain-disease for which treatment both pharmacological 
protocols and invasive methods are used. Among the latter, 
the RF (Radiofrequency) pulse-dose has been of interest for 
the prospects of analgesic efficacy, safety and patient 
compliance, although at the moment only data concerning 
the pulsed RF and not the RF pulse-dose, that represents its 
evolution, are discussed in scientific literature. The purpose 
of this study is a "simple" economic evaluation of this 
method in headache occipital neuralgia.  
 




I.  INTRODUCTION 
 
 Essential headache recognizes a significant economic 
impact, the assessment of which of course are not only 
included the costs of treatment. There is no single 
therapeutic option and, if on the one hand the drug 
therapy is to be distinguished in therapy of acute and 
prophylactic therapy, the other for the latter no protocol 
showed a clear superiority over other  (1-2-3). This is 
particularly interesting considering that the same 
Guidelines issued by scientific societies (4) are evolving 
as regards both the acute and prophylactic therapy, and 
that, where indicated and possible, is expected to draw 
even invasive methods instead of medications (5-6). 
These procedures must comply with safety rules and still 
have accost to be taken into account to assess not only 
their effectiveness, but also the real efficiency (7). Pulse-
dose Radiofrequency represents the technological 
evolution of Pulsed Radiofrequency. It allows to provide 
pulses or "Doses" with defined and accurate current or 
voltage values. In fact, in Pulse Dose pulses are 
maintained constant over time at 45 volts, of 20 ms 
duration and a temperature not exceeding 42 ° C, 
compared to pulsed radio frequency in which the pulse 
amplitude is 45 volts and the maximum temperature of 42 
° C, but if it exceeds 42 ° C, the successive pulses will 
have a potential of less than 45 volts. On the contrary, in 
the Pulse Dose, the temperature is kept constant thanks to 
the infusion of saline solution near the tissue subjected to 
the procedure. This allows furthermore to shorten 
procedure time and sometimes to avoid the use of the 
surgery room. In Pulse Dose radiofrequency pulses are 
defined previously by the user either as applicable Volt to 
the electrode, either as applied temperature and as number 
of doses ranging from a minimum of 120 to a maximum 
of 2400. In this way doses are provided constant in both 
voltage value and temperature and the final result is 
represented by an increase of 70% effectiveness 
application. Just the ability to set the number of "doses" to 
be provided is the advantage of this method which can 
thus be standardized for each peripheral nerve to be 
treated. Its ideal applications are on peripheral nerve 
fibers, such as: Great Occipital, suprascapular; Pudendal, 
Facet Syndrome, Carpal Tunnel. The recent introduction 
into clinical practice of this method refers to the need to 
evaluate the analgesic efficacy and possible economic 
advantage, also in consideration of the fact that, being 
neuro-modulatory, the RF pulse dose is not a procedure 
"final", but presumably its effects will have a limited 
lifespan and this may affect the cost-benefits ratio.  
 
II.  METHODOLOGY 
 
 The aim of our study was to verify the presence of 
any economic advantage for the Health System of the 
Campania region resulting from the RF pulse dose 
compared to headaches drug protocols. In our economic 
analysis we have used the break even analysis, which 
identifies the point (= break even point), in which the 
revenues obtained (avoided costs) equal the total costs 
incurred for a period of 24 months. We considered as 
avoided costs the prices of drugs administered to a group 
of 22 patients (12 M -10 F, age 27-52aa, not suffering 
from liver failure, kidney or heart failure), afferent (from 
January to September 2011) to Pain clinic of the 
University "Federico II" of Naples, suffering from 
occipital neuralgia and subjected first to drug therapy and, 
in a second time, the pulse dose RF. The total costs, 
although generally comprising a fixed part and a variable 
part, in our case, detailing the costs of treatment with 
Pulse Dose RF, are only fixed. (ticket for diagnostic 
anesthetic block to be performed before the RF, DRG for 
the procedure). Regarding drug therapy, we considered 
the monthly cost per patient, the weighted average based 
on three different protocols followed by our patients (and 
validated in the literature). Cost are reported by (8) 15 
patients were taking topiramate100mg/die, propranolol 
CR 80mg/die, dexamethasone 4mg/die, rabeprazol 20 mg 
/ die; 4 patients receiving topiramate, dexamethasone, and 
rabeprazole in dosages above and  flunarazin 10 mg / die 
instead of the beta-blocker; 3 patients taking lamotrigine 
100mg/die, pregabalin 300mg/die in addition to the 
steroid and the inhibitor of the pump. These 22 patients 
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asked, at a later time, an alternative to pharmacological 
therapy, for these reasons: 10 felt they did not obtain the 
desired relief, 5 no longer wanted to take "many" drugs, 7 
had achieved a fair level of analgesia but at the cost of 
increased side effects. These patients were then subjected 
to a session of Pulse Dose RF, providing pulses ("doses") 
effective and stable in time and amplitude of 45 V and a 
duration of 20 ms, for a total of 1200 doses. The 
infiltration points were chosen based on anatomical 
descriptions of  Vitale and coll., Becser and coll., Loucas 
and coll., Natsis and coll. (9-10-11-12).  
 
 
III.  RESULTS 
 
   At the end of our economic evaluation, the fixed costs 
amount to 2,115 euros, while the avoided costs for 12 
months amounted to Euro 1416, where the break even 
point is set at 18 months (Fig. 1).  
In practice this means that the Pulse Dose RF would be 
economically advantageous for the Campania Region SS 
with respect to drugs only if the term had analgesic 
efficacy equal to or greater than 18 months. 
In our patients the Pulse Dose RF resulted in a reduction 
of VAS greater than 60% compared to baseline with a 
significant improvement in quality of life within three and 
six months from performing the procedure.  
 
 
IV.  DISCUSSION 
 
 From a strictly economic point of view, our study 
presents a simple model of cost-effectiveness and 
indicates that in practice if you want to conduct efficiency 
studies of the Pulse Dose RF, you should perform a 
follow-up of at least 18 months. On the other hand, for the 
specialist in pain management, the minimum time limit of 
18 months has a relative weight if it occurred to her 
patients a significant reduction in pain with improved 
quality of life and overall satisfaction for a significant 
shorter period. In fact, considering the socio-economic 
impact of a disease and its treatment, medication-
economic studies should take into account several aspects: 
Van Zundert (13), in an article in 2005, brought this 
action to a specific Medical Technology Assessment 
(MTA), which can determine both the total importance 
("weight") of the disease (for the patient and the society) 
and the overall cost of the treatments, also evaluating their 
efficacy.  
In describing this method, the Author follows the pattern 
presented previously by Tugwell and coll.(14) that 
considers the cost of the disease in terms linked to society 
and quality of life of patients and in terms of costs of 
attaining a correct diagnosis (laboratory and / or 
radiological tests) but also the effectiveness of treatments 
in terms of therapeutic effect, according to guidelines 
already  drawn up or being implemented, and cost-benefit 
(15). It must also take into account in assessing the costs 
of chronic disease should be included: 
 
- Direct costs, specifically attributable to its 
diagnosis and/or therapy (instrumental and 
laboratory tests, prices of drugs and invasive 
procedures). 
- Indirect costs, which relate to the psychological 
and social scope of the patient (quality of life, 
work and recreational activities), and the impact 
caused to the company (decreased job activity). 
It 's clear that the former are easily quantifiable, while the 
latter can be investigated only through the administration 
of particular questionnaires that assume a statistically 
significant value only on large patient populations, in the 
condition of homogeneity. Improving the quality of life 
and patient satisfaction ultimately represents a reduction 
of indirect costs and, if you had the opportunity to 
monetize QoLi score improvement, this would affect 
positively on the economic advantage. Currently, the tests 
used to measure various aspects of quality of life are 
subjective and, to have statistical significance, requires a 
large and homogeneous sample.  
 
 
V.  CONCLUSION 
 
 Currently, this work aims only propose some 
reflections on a promising technique used for occipital 
headache as other painful conditions, but for which the 
scientific literature needs better and more systematic 
studies. Finally, considering the limited data in the 
literature, we could evaluate the efficacy and efficiency of 
the pulse dose RF and continuous RF in occipital 
headache. The pulse dose RF is a technique of 
neuromodulation, so that its effect is reversible and 
repeatable. Giving a response limited in time, however, it 
will be necessary for the patient to undergo several 
sessions after months (the duration of effect is subjective). 
The continue RF, instead, is a neurolesive technique: it 
offers the advantage of a long-lasting analgesic effect but 
also the risk of developing deafferentation pain. 
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